Hzymes Biotechnology

Hzymes Biotechnology is an innovative high-tech firm specializing in the production of crucial raw materials for the in vitro diagnostic industry. Founded in 2015, the company leverages five distinct technology platforms to scale-up the production of high-quality enzymes. Their slogan, "Advancing Health with High-Quality Enzyme Production for Reliable In Vitro Diagnostics," encapsulates their commitment to global raw material supply security and their dedication to improving human health and well-being. In their latest funding round on 10 November 2021, the company secured an impressive CNY800.00M Series C investment from a consortium of prominent investors, including GL Capital, Tenyall, CASH Capital, Industrial Bank, and the Chinese Academy of Sciences. This notable backing reflects the industry's confidence in Hzymes' potential to disrupt the manufacturing landscape and drive significant advancements in the in vitro diagnostic sector. At the intersection of manufacturing and biotechnology, Hzymes Biotechnology stands as a promising player in the quest to provide reliable raw materials for in vitro diagnostics, reaffirming its position as a compelling investment opportunity for venture capitalists seeking to support sustainable, high-impact ventures.